Literature DB >> 8139647

Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis.

D L Horn, D Hewlett, C Alfalla, S Peterson, S M Opal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8139647     DOI： 10.1056/nejm199404283301718

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

Review 1.  Current medical treatment for tuberculosis.

Authors:  Edward D Chan; Michael D Iseman
Journal:  BMJ       Date:  2002-11-30

2.  Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors:  Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

Review 3.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 4.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

5.  Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.

Authors:  Tianyu Zhang; Si-Yang Li; Kathy N Williams; Koen Andries; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2011-06-09       Impact factor: 21.405

Review 6.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Treatment and prevention of multidrug-resistant tuberculosis.

Authors:  I Bastian; R Colebunders
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

8.  Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

Authors:  Tina Papastavros; Lisa R Dolovich; Anne Holbrook; Lori Whitehead; Mark Loeb
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

9.  Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Authors:  Zahoor Ahmad; Sandeep Tyagi; Austin Minkowski; Charles A Peloquin; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

10.  Saudi guidelines for testing and treatment of latent tuberculosis infection.

Authors:  Hamdan H Al Jahdali; Salim Baharoon; Abdullah A Abba; Ziad A Memish; Abdulrahman A Alrajhi; Ali AlBarrak; Qais A Haddad; Mohammad Al Hajjaj; Madhukar Pai; Dick Menzies
Journal:  Ann Saudi Med       Date:  2010 Jan-Feb       Impact factor: 1.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.